Agios Pharmaceuticals (NASDAQ:AGIO) CEO Sells $506,664.27 in Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CEO Brian Goff sold 18,703 shares of the company’s stock in a transaction that occurred on Tuesday, December 30th. The stock was sold at an average price of $27.09, for a total transaction of $506,664.27. Following the sale, the chief executive officer directly owned 136,583 shares of the company’s stock, valued at approximately $3,700,033.47. This trade represents a 12.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Agios Pharmaceuticals Price Performance

NASDAQ:AGIO traded down $0.04 during mid-day trading on Friday, reaching $27.18. The stock had a trading volume of 891,433 shares, compared to its average volume of 1,512,286. Agios Pharmaceuticals, Inc. has a 12 month low of $22.24 and a 12 month high of $46.00. The stock has a market capitalization of $1.58 billion, a PE ratio of -3.88 and a beta of 0.89. The stock has a 50-day simple moving average of $32.20 and a two-hundred day simple moving average of $35.96.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.15. Agios Pharmaceuticals had a negative return on equity of 28.35% and a negative net margin of 895.86%.The firm had revenue of $12.88 million for the quarter, compared to the consensus estimate of $10.49 million. During the same quarter last year, the business posted $16.22 EPS. The company’s revenue was up 43.3% compared to the same quarter last year. Equities analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Institutional Trading of Agios Pharmaceuticals

Several institutional investors have recently modified their holdings of AGIO. Bellevue Group AG lifted its holdings in Agios Pharmaceuticals by 3.5% during the 3rd quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock worth $149,110,000 after buying an additional 124,586 shares during the period. Erste Asset Management GmbH increased its stake in shares of Agios Pharmaceuticals by 18.8% in the third quarter. Erste Asset Management GmbH now owns 2,764,900 shares of the biopharmaceutical company’s stock valued at $108,578,000 after buying an additional 438,411 shares during the period. Wellington Management Group LLP raised its position in shares of Agios Pharmaceuticals by 485.5% during the third quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock worth $99,203,000 after acquiring an additional 2,049,287 shares during the last quarter. Commodore Capital LP lifted its stake in shares of Agios Pharmaceuticals by 0.6% in the third quarter. Commodore Capital LP now owns 2,338,287 shares of the biopharmaceutical company’s stock worth $93,859,000 after acquiring an additional 13,287 shares during the period. Finally, TCG Crossover Management LLC lifted its stake in shares of Agios Pharmaceuticals by 105.2% in the third quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock worth $57,402,000 after acquiring an additional 733,038 shares during the period.

Analysts Set New Price Targets

AGIO has been the topic of a number of recent analyst reports. Royal Bank Of Canada cut Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and decreased their target price for the company from $57.00 to $28.00 in a research report on Wednesday, November 19th. JPMorgan Chase & Co. reduced their price target on shares of Agios Pharmaceuticals from $37.00 to $20.00 and set a “neutral” rating on the stock in a research note on Friday, November 21st. HC Wainwright lifted their price target on shares of Agios Pharmaceuticals from $48.00 to $62.00 and gave the company a “buy” rating in a report on Wednesday, December 24th. Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Monday. Finally, Truist Financial raised their target price on shares of Agios Pharmaceuticals from $32.00 to $38.00 and gave the company a “buy” rating in a research report on Wednesday, December 24th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Agios Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $38.89.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.